{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:26:49Z","timestamp":1788492409377,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA007848"],"award-info":[{"award-number":["P30 CA007848"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.breast.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T08:32:02Z","timestamp":1674462722000},"page":"469-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Axillary lymph node dissection: Dead or still alive?"],"prefix":"10.1016","volume":"69","author":[{"given":"Anna C.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.breast.2023.01.009_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","article-title":"The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894","volume":"20","author":"Halsted","year":"1894","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.breast.2023.01.009_bib2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.breast.2023.01.009_bib3","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.2010.28.2491","article-title":"Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: national Surgical Adjuvant Breast and Bowel Project phase III protocol B-32","volume":"28","author":"Land","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.breast.2023.01.009_bib4","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","article-title":"Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011","volume":"25","author":"Lucci","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2023.01.009_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.breast.2023.01.009_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa020128","article-title":"Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.breast.2023.01.009_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJM198503143121102","article-title":"Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation","volume":"312","author":"Fisher","year":"1985","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2023.01.009_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00000658-199409000-00015","article-title":"Lymphatic mapping and sentinel lymphadenectomy for breast cancer","volume":"220","author":"Giuliano","year":"1994","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2023.01.009_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","article-title":"Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial","volume":"252","author":"Giuliano","year":"2010","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR trial: the Optimal Treatment of the Axilla - surgery or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial","volume":"43","author":"S\u00e1volt","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.01.009_bib12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-A rare event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","article-title":"Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial","volume":"260","author":"Boughey","year":"2014","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.breast.2023.01.009_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","article-title":"Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study","volume":"173","author":"Classe","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.breast.2023.01.009_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2023.01.009_bib17","series-title":"NCCN clinical practice guidelines for oncology: breast cancer: version 4","year":"2022"},{"issue":"10","key":"10.1016\/j.breast.2023.01.009_bib18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/SLA.0b013e3181c0e92a","article-title":"Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study","volume":"251","author":"Veronesi","year":"2010","journal-title":"Ann Surg"},{"issue":"9069","key":"10.1016\/j.breast.2023.01.009_bib20","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0140-6736(97)01004-0","article-title":"Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes","volume":"349","author":"Veronesi","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2023.01.009_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06290-9","article-title":"National trends for axillary lymph node dissection and survival outcomes for clinical T3\/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes","volume":"189","author":"Reyna","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2023.01.009_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-020-05876-z","article-title":"Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy","volume":"184","author":"Riedel","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.breast.2023.01.009_bib23","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2023.01.009_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2023.01.009_bib25","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.breast.2023.01.009_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jso.21911","article-title":"The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis","volume":"104","author":"Tan","year":"2011","journal-title":"J Surg Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.01.009_bib27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/bjs.10986","article-title":"Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer","volume":"105","author":"Tee","year":"2018","journal-title":"Br J Surg"},{"issue":"7","key":"10.1016\/j.breast.2023.01.009_bib28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/cncr.22540","article-title":"Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases","volume":"109","author":"Shen","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib29","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","article-title":"Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance)","volume":"263","author":"Boughey","year":"2016","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.breast.2023.01.009_bib30","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2023.01.009_bib31","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1245\/s10434-012-2484-2","article-title":"The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer","volume":"19","author":"Alvarado","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.breast.2023.01.009_bib32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/1759-7714.12131","article-title":"Sentinel lymph node biopsy does not apply to all axillary lymph node-positive breast cancer patients after neoadjuvant chemotherapy","volume":"5","author":"Ge","year":"2014","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib33","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1245\/s10434-020-09024-1","article-title":"Treatment patterns and outcomes of women with breast cancer and supraclavicular nodal metastases","volume":"28","author":"Tamirisa","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.breast.2023.01.009_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48021","article-title":"Trends in sentinel lymph node biopsies in patients with inflammatory breast cancer in the US","volume":"5","author":"Sosa","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.breast.2023.01.009_bib35","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","article-title":"Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer","volume":"18","author":"DeSnyder","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.breast.2023.01.009_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer","volume":"7","author":"Hidar","year":"2009","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.breast.2023.01.009_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02573060","article-title":"Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer","volume":"9","author":"Stearns","year":"2002","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.01.009_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1245\/s10434-013-3200-6","article-title":"Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy","volume":"21","author":"Dengel","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.breast.2023.01.009_bib39","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1245\/s10434-022-12238-0","article-title":"Omission of intraoperative frozen section may reduce axillary overtreatment among clinically node-negative patients having upfront mastectomy","volume":"29","author":"Williams","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.breast.2023.01.009_bib40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs No axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.breast.2023.01.009_bib41","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","article-title":"Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.01.009_bib42","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1245\/s10434-022-12064-4","article-title":"Factors influencing non-sentinel lymph node involvement in patients with positive sentinel lymph node(s) after neoadjuvant chemotherapy for breast cancer","volume":"29","author":"Sanders","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.breast.2023.01.009_bib43","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","article-title":"Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.breast.2023.01.009_bib58","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.ejca.2008.06.033","article-title":"Variations in sentinel node isolated tumour cells\/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions","volume":"44","author":"Cserni","year":"2008","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.breast.2023.01.009_bib44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archsurg.141.9.867","article-title":"Management and outcomes of isolated axillary node recurrence in breast cancer","volume":"141","author":"Konkin","year":"2006","journal-title":"Arch Surg"},{"issue":"4","key":"10.1016\/j.breast.2023.01.009_bib45","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0002-9610(00)00456-6","article-title":"Presentation, management and outcome of axillary recurrence from breast cancer","volume":"180","author":"Newman","year":"2000","journal-title":"Am J Surg"},{"issue":"34","key":"10.1016\/j.breast.2023.01.009_bib46","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2023.01.009_bib47","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.01.009_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-018-0090-6","article-title":"21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer","volume":"4","author":"Geyer","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2023.01.009_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2023.01.009_bib50","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1245\/s10434-016-5330-0","article-title":"Impact of body mass index on clinical axillary nodal assessment in breast cancer patients","volume":"23","author":"McCartan","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2023.01.009_bib51","article-title":"Axillary staging is not justified in postmenopausal clinically node-negative women based on nodal disease burden","author":"Lee","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.breast.2023.01.009_bib52","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1245\/s10434-022-12193-w","article-title":"How often do sentinel lymph node biopsy results affect adjuvant therapy decisions among postmenopausal women with early-stage HR(+)\/HER2(-) breast cancer in the post-RxPONDER era?","volume":"29","author":"Pilewskie","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.breast.2023.01.009_bib53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0042-122853","article-title":"Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c\/iT1-2) in the context of breast conserving therapy: first results following commencement of the intergroup-sentinel-mamma (INSEMA) trial","volume":"77","author":"Reimer","year":"2017","journal-title":"Geburtshilfe Frauenheilkd."},{"issue":"1","key":"10.1016\/j.breast.2023.01.009_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","article-title":"Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial","volume":"17","author":"de Boniface","year":"2017","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.breast.2023.01.009_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054365","volume":"11","author":"Goyal","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2023.01.009_bib56","unstructured":"Alliance for Clinical Trials in Oncology. Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. Alliance A11202 Trial, NCT01872975. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01901094 [Accessed November 9, 2022]."},{"key":"10.1016\/j.breast.2023.01.009_bib57","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","article-title":"Tailored axillary surgery in patients with clinically node-positive breast cancer: pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)","volume":"60","author":"Weber","year":"2021","journal-title":"Breast"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:49:35Z","timestamp":1760777375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977623000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":58,"alternative-id":["S0960977623000097"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.01.009","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axillary lymph node dissection: Dead or still alive?","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}